(Reuters) - LONDON/ZURICH, July 9 - Roche Holding AG has signed a deal worth up to $1 billion with Alnylam Pharmaceuticals Inc. , giving it access to the U.S. firm's skills in the new science of RNA interference.
The agreement is the largest drug discovery partnership in the field to date and a further vindication of the emerging area of biotechnology research, which involves blocking disease-causing proteins.
Read more at Reuters.com Mergers News
The agreement is the largest drug discovery partnership in the field to date and a further vindication of the emerging area of biotechnology research, which involves blocking disease-causing proteins.
Read more at Reuters.com Mergers News
No comments:
Post a Comment